Effectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis

BACKGROUND: The oral nucleos(t)ide analogue, entecavir (ETV) was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-associated liver cirrhosis. However, the reduction of HCC differs in various regions of the world. AIM: To investigate the reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarao, Kazuo, Nozaki, Akito, Chuma, Makoto, Taguri, Masataka, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856867/
https://www.ncbi.nlm.nih.gov/pubmed/33584993
http://dx.doi.org/10.4254/wjh.v13.i1.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856867/
https://www.ncbi.nlm.nih.gov/pubmed/33584993
http://dx.doi.org/10.4254/wjh.v13.i1.144

Ejemplares similares